Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 841 - 860 results of 101,136 for search '(( 5 ((wt decrease) OR (mean decrease)) ) OR ( 5 ((a decrease) OR (nn decrease)) ))', query time: 1.46s Refine Results
  1. 841
    Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation.

    Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

    Published 2016
    Save to List
    Saved in:
  2. 842
    Decreased erythropoiesis related gene expression in the bone marrow of <i>Thra1</i><sup>PV/+</sup> mice.

    Decreased erythropoiesis related gene expression in the bone marrow of <i>Thra1</i><sup>PV/+</sup> mice. by Sunmi Park (2051092)

    Published 2017
    Save to List
    Saved in:
  3. 843
    Sign-tracking (ST)–Goal-tracking (GT) score for day 5.

    Sign-tracking (ST)–Goal-tracking (GT) score for day 5. by Silvia Fuentes (4759686)

    Published 2018
    Save to List
    Saved in:
  4. 844
    Decreased expression of GLT-1, GLAST and GS in the hippocampus of 4-week-old Bmi-1<sup>−/−</sup> mice.

    Decreased expression of GLT-1, GLAST and GS in the hippocampus of 4-week-old Bmi-1<sup>−/−</sup> mice. by Guangliang Cao (182635)

    Published 2012
    “…Three mice per genotype and 3 independent experiments for each homogenized brain sample. Data represent means ± SEM. *P<0.05; vs. WT mice.</p>…”
    Save to List
    Saved in:
  5. 845
    Genetic deletion of the CB1 receptor reduces the stability of NREM bouts by decreasing the time spent in NREM and increasing WK.

    Genetic deletion of the CB1 receptor reduces the stability of NREM bouts by decreasing the time spent in NREM and increasing WK. by Matthew J. Pava (521194)

    Published 2014
    Save to List
    Saved in:
  6. 846
    Decreased macrophage content per lesion area in atherosclerotic lesions from ABCA1 KO→LDLr KO mice.

    Decreased macrophage content per lesion area in atherosclerotic lesions from ABCA1 KO→LDLr KO mice. by Bart Lammers (302835)

    Published 2013
    Save to List
    Saved in:
  7. 847
    Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection.

    Mucosal vaccination with M2e5x VLP decreases innate immune cell recruitments after influenza virus infection. by Young-Tae Lee (467116)

    Published 2018
    Save to List
    Saved in:
  8. 848
    ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses.

    ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

    Published 2023
    Save to List
    Saved in:
  9. 849
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 850
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 851
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 852
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 853
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 854
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 855
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 856
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 857
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 858
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 859
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 860
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: